Remus Pharmaceuticals Limited (NSE:REMUS)

India · Delayed Price · Currency is INR

1,002.00

-9.55 (-0.94%)

Oct 16, 2026, 3:29 PM IST

Market Cap	11.81B +48.4%
Revenue (ttm)	8.54B +37.6%
Net Income	369.90M +27.2%
EPS	31.39 -36.4%
Shares Out	11.78M
PE Ratio	31.92
Forward PE	n/a
Dividend	1.00 (0.10%)
Ex-Dividend Date	Sep 22, 2026

Volume	3,700
Open	1,006.00
Previous Close	1,011.55
Day's Range	1,000.00 - 1,016.00
52-Week Range	580.00 - 1,039.00
Beta	0.28
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceutical products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredients, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company also offers tablet, hard and soft gel capsules, liquid, dry powder, lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays, topical sprays, respules, syr... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 2015

Employees 69

Stock Exchange National Stock Exchange of India

Ticker Symbol REMUS

Full Company Profile

Financial Performance

In fiscal year 2026, Remus Pharmaceuticals's revenue was 8.54 billion, an increase of 37.60% compared to the previous year's 6.20 billion. Earnings were 369.90 million, an increase of 27.24%.

Financial Statements